Systasy offers leading edge technology and unparalleled expertise. Our proprietary technology provides the fastest and most cost-effective approach to mapping disease pathways from the cellular level to the patient cohort level to enable next generation medicine. We address the challenges of complex human genetic diseases.  We also identify drug candidates for repurposing. We also have a strong interest in rare diseases.

At Systasy, we look for new opportunities to collaborate in the field of drug discovery and development. As we have strong ties with the Department of Psychiatry in Munich, we have  in-depth knowledge in the field of mental disorders and neurology. Another focus is the field of ophthalmology and herein especially the identification of new AAV variants.

Systasy’s management brings a collective 40+ years of experience in neuroscience, human disease models, and barcoding technologies, and collaborates with experts in the area. Systasy seeks a partner/investor to accelerate their projects.